Label-Free Detection Market Overview
Label-Free Detection Market size is estimated to reach $717.4 million by 2027, growing at a CAGR of 7.5% during the forecast period 2022-2027. Label-Free Detection (LFD) is a technique used for discovering biomolecules and their communications. Numerous label-free techniques for the discovery of biomolecular interactions are presently accessible, based on technologies like surface plasmon resonance (SPR), interferometry, diffraction, and quartz crystal microbalance. Out of these, surface plasmon resonance (SPR) detection is the most extensively utilized. Surface plasmon resonance (SPR) is the ringing vibration of conduction electrons at the junction between negative and positive allowable material excited by incident light. Surface plasmon resonance imaging (SPRi) is a label-free method for in situ detection and investigation of molecular bindings. Novel techniques for SARS-CoV-2 detection, which depend on straight-forward, label-free imaging of viral particles have been performed. Spatial light-interference microscopy (SLIM), a greatly sensitive interferometric technique, to image viruses accumulated on a glass slide has been applied. Bio-Layer Interferometry (BLI) is a label-free technology for assessing biomolecular interactions. Bio-Layer Interferometry is an optical analytical method that evaluates the intervention pattern of white light reflected from two surfaces: a layer of disenabled protein on the biosensor tip, and an internal reference layer. Any alteration in the count of molecules bound to the biosensor tip brings about a shift in the intervention pattern that can be assessed in real-time. The increasing utilization of label-free detection in the drug discovery sector is set to drive the Label-Free Detection Market. The burgeoning awareness regarding the comprehensive data collected by way of label-free detection methods like surface plasmon resonance is set to propel the growth of the Label-Free Detection Market during the forecast period 2022-2027. This represents the Label-Free Detection Industry Outlook.
Label-Free Detection Market Report Coverage
The report: “Label-Free Detection Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Label-Free Detection Market.
Product: Consumables (Biosensor Chips, Microplates),
By Technology: Mass Spectrometry, Surface Plasmon Resonance (SPR), Bio-Layer Interferometry, Isothermal Titration Calorimetry, Others.
By Application: Binding Kinetics, Binding Thermodynamics, Endogenous Receptor Detection, Hit Confirmation, Lead Generation, Others.
By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Others.
By Geography: North America (U.S, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Rest of South America) and Rest Of The World (Middle East, Africa).
- Geographically, North America Label-Free Detection Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the great demand from research centers and pharmaceutical firms for label-free detection techniques like surface plasmon resonance in the North American region.
- Label-Free Detection Market growth is being driven by the launch of technologically progressive products and increased utilization of label-free detection techniques like surface plasmon resonance, and the boost in the count of drug-discovery programs by way of academic-industrial partnerships. However, the soaring cost of tools and the lack of knowledge, and reduced degree of awareness among end-users concerning the different advantages of label-free detection methods are some of the major factors hampering the growth of the Label-Free Detection Market.
- Label-Free Detection Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Label-Free Detection Market report.
Label-Free Detection Market Share, By Geography, 2021(%)
For More Details on This Report - Request for Sample
Label-Free Detection Market Segment Analysis – By Product
The Label-Free Detection Market based on products can be further segmented into Consumables and Instruments. The Consumables Segment held the largest market share in 2021. This growth is owing to the increased application of biosensor chips. With the integration of the realistic high-throughput technique, the array fluorescent biosensor may be utilized for analysis on the biomolecular interactions and their ligands for flexible applications, like biosensing, medical diagnosis, and drug screening. The features of biosensor chips like the great specificity and the capability to supervise biomolecular interactions in real-time are propelling the growth of this segment.
Furthermore, the Instruments segment is estimated to grow with the fastest CAGR of 8.2% during the forecast period 2022-2027 owing to the increased utilization of multi-functional instrument platforms based on Bio-Layer Interferometry (BLI), a label-free technology that assesses molecular interactions in real-time with the aim of detection, quantitation, and kinetic analysis.
Label-Free Detection Market Segment Analysis – By Technology
The Label-Free Detection Market based on technology can be further segmented into Mass Spectrometry, Surface Plasmon Resonance (SPR), Bio-Layer Interferometry, Isothermal Titration Calorimetry, and Others. The Surface Plasmon Resonance (SPR) Segment held the largest market share in 2021. This growth is owing to the great sensitiveness of this technology and its extensive application in regulating specificity, affinity, and kinetic parameters at the time of the binding of macromolecules. The increased compatibility of surface plasmon resonance (SPR) technology with an expansive spectrum of biomolecules is further propelling the growth of this segment.
Furthermore, the Bio-Layer Interferometry segment is estimated to grow with the fastest CAGR of 8.4% during the forecast period 2022-2027 owing to the advantages offered by bio-layer interferometry like limited inconstancy in the refractive index of the samples being tested and microfluidic-free characteristic of bio-layer interferometry label-free detection systems.
Label-Free Detection Market Segment Analysis – By Geography
The Label-Free Detection Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Label-Free Detection Market) held the largest share with 33% of the overall market in 2021. The growth of this region is owing to the proliferating technological progress and the great government funding in the region. The boost in the predominance of ailments, extensive partnerships between pharmaceutical firms and academic institutes, the existence of numerous pharmaceutical and biotechnological firms utilizing label-free techniques like bio-layer interferometry (BLI) and surface plasmon resonance (SPR), and the development of drug discovery programs are further propelling the growth of the Label-Free Detection Market in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increased degree of awareness regarding label-free techniques like bio-layer interferometry (BLI) and surface plasmon resonance (SPR) and a boost in initiatives adopted by the government to enhance healthcare infrastructure. The soaring investments in biotechnology and drug discovery are further fuelling the progress of the Label-Free Detection Market in the Asia-Pacific region.
Label-Free Detection Market Drivers
Increasing Application Of Label-Free Detection For Binding Interaction Analysis Is Projected To Drive The Growth Of Label-Free Detection Market:
Biomolecular interactions act as essential causes for abundant biological techniques and thus offer excellent targets for drug discoveries. Biological binding interactions are an active procedure propelled by modifications to the surroundings. Hence, procedures utilized to typify these interactions require to mirror the level of biological complication in order to completely comprehend these systems. Typically utilized label-free binding analysis platforms are Bio-Layer Interferometry (BLI), Surface Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC), and Microscale Thermophoresis (MST). Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) supervise binding interactions based on the molecular aggregation that occurs at the time of complex formation. The binding complex is set up at the biosensor surface by immobilization of one binding partner (ligand) and directly supervising the binding of the analyte furnished from the solution. The complex formation and dissociation are supervised in real-time, supplying kinetics and affinity data. The increased usage of label-free detection for binding interaction analysis is thus fuelling the growth of the Label-Free Detection Market during the forecast period 2022-2027.
Technological Innovations And Collaborations Are Expected To Boost The Growth Of Label-Free Detection Market:
Technological innovations and collaborations are driving the growth of the Label-Free Detection market. Typically utilized label-free detection techniques include surface plasmon resonance (SPR) and bio-layer interferometry (BLI). Novel Corning® Epic® BT is the earliest optically-based, single-mode benchtop model for cell-based and biochemical assays in the industry. The benchtop label-free detection system developed by Corning is characterized by a packed design, a more economical price point, clear data accumulation software, and complete microplate investigation utilizing charge-coupled device (CCD) discovery of wavelength shift. The novel system enhances assay capabilities and permits researchers, inclusive of academic laboratories, effortless means of entry to the Epic technology. Corning chose Advinus Therapeutics as a partner for preparing for the saleability of the Corning Epic® label-free detection technology in India. The collaboration between the two firms permitted Advinus to utilize Epic for its own drug discovery programs and for the supply of assay advancement and screening services to clients in India and internationally. These kinds of technological innovations and collaborations are driving the growth of the Label-Free Detection Market.
Label-Free Detection Market Challenges
Disadvantages Of Label-Free Techniques Are Challenging The Growth Of The Label-Free Detection Market:
In label-free investigations, every sample is assessed in disconnected mass spectrometry (MS) run. This consumes more machine time. One limitation of the label-free technique run conditions like temperature, experimenter, column condition can be different between samples. These kinds of discrepancies do not happen in labeled investigations, owing to the comparison of samples to each other happening in the very same MS run. Thus, label-free techniques are more susceptible to inaccuracies brought in by the assessment conditions than labeled. Involving a well-chosen standard in label-free investigations like a labeled control sample blended with every sample before the MS run or the “Super-SILAC” technique can lessen this issue, but has to be cautiously prepared earlier. These limitations of label-free techniques are hampering the growth of the Label-Free Detection Market.
Label-Free Detection Market Landscape:
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Label-Free Detection Market. Key companies of this market include:
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Perkin Elmer Inc
- Corning Incorporated
- Cytiva (GE Healthcare)
- Waters Corporation
- HORIBA Ltd.
- Agilent Technologies, Inc.
- In March 2021, the Life Science Group Sartorius introduced the novel great-performance Octet® R range of systems, the most recent enhancement in the line of label-free analytical products of the firm. With three distinct models to select from, users will be able to find the correct harmony between throughput requirements and their financial plans.
- In October 2020, HORIBA declared the automatic driving system, ADS EVO, which is a driving robot for vehicle testing. The ADS EVO enhances the effectiveness of vehicle testing by decreasing the count of repeat tests, laboratory operating costs, complete test time, and the number of human errors.
Report Code: HCR 35864
Report Code: ESR 80812
For more Lifesciences and Healthcare Market reports, please click here